20-Bio-B5 Rehabilitation Engineering · May 2013
Nivaar worked solution (AI-drafted; not reviewed by a licensed engineer)
Paper format: National Exams, May 2013 — 04-Bio-B5 Cell and Tissue Engineering (the exam's own header). Three hours, open book, any Casio/Sharp non-communicating calculator. Six questions of equal value (20 marks each, 120 marks printed); five constitute a complete paper and only the first five appearing in the answer book are marked (100 marks total). All six are solved here, because this set is a study resource rather than an examination script. Every question is essay/descriptive (design, regulatory, and mechanistic reasoning in tissue engineering) with no numerical data to compute — the marking-scheme arithmetic is the only concrete number in the paper.
Reference texts (the books an open-book candidate should have on the desk for this subject):
Question text not reproduced: the examination questions are © Engineers and Geoscientists BC. Open the official past paper (linked at the top of this page) to read the question, then follow the worked solution below.
Improved stem cell isolation and characterization techniques (fluorescence-activated and magnetic-activated cell sorting, FACS/MACS, using well-defined surface-marker panels) allow mesenchymal stem cells (MSCs) to be reliably isolated from accessible sources such as bone marrow and adipose tissue, expanded to clinically useful numbers, and purified from contaminating cell types with far greater consistency than earlier bulk-isolation methods — this directly addresses the cell-sourcing problem raised in Questions 1 and 2, providing an abundant, multipotent, comparatively immune-privileged (low MHC-II expression, immunomodulatory) cell source without the ethical and availability constraints of embryonic stem cells or the donor-site morbidity of harvesting mature differentiated cells. Advances in induced pluripotent stem cell (iPSC) technology extend this further by allowing patient-specific, autologous pluripotent cells to be generated from a simple somatic biopsy, in principle eliminating allogeneic rejection risk entirely while retaining the broad differentiation capacity historically associated only with embryonic stem cells.
On the gene therapy side, improved vector safety and specificity (better-characterized adeno-associated viral (AAV) vector serotypes with defined tissue tropism, and safer non-viral methods such as lipid-nanoparticle or electroporation-based delivery) make it practical to genetically modify seeded cells — either ex vivo before seeding onto a scaffold, or in situ by embedding vector directly in the construct — so that the cells themselves become a local, sustained production source for a therapeutic protein, growth factor, or matrix component, rather than relying on the cells' native (and often insufficient) output or on a single bolus of exogenously delivered protein. Because gene-modified cells continue to produce the therapeutic factor as long as they survive and the transgene remains expressed, this approach can provide graded, sustained local signalling that tracks the construct's own remodelling timescale far more closely than a single delivered dose can, directly complementing (rather than replacing) the scaffold- and cell-based approaches discussed throughout this paper.
For bone tissue engineering, mesenchymal stem cells are transduced ex vivo (commonly via an adenoviral or lentiviral vector) with the gene encoding bone morphogenetic protein-2 (BMP-2), a potent osteoinductive growth factor, before being seeded onto an osteoconductive scaffold (e.g., a calcium-phosphate ceramic or hydroxyapatite-coated polymer, following the same scaffold-design logic developed for bone in Question 2(a)). The transduced cells then continuously synthesize and locally secrete BMP-2 as they populate and remodel the scaffold, driving both their own osteogenic differentiation (autocrine signalling) and recruitment/differentiation of neighbouring host osteoprogenitor cells (paracrine signalling), while the scaffold provides the structural template and osteoconductive surface for the resulting mineralized matrix to form on.
This gene therapy approach is expected to outperform a single bolus of recombinant BMP-2 protein delivered directly to the defect (the conventional clinical alternative) for two engineering reasons. First, a bolus dose must be very high to compensate for BMP-2's short local half-life and rapid diffusion away from the defect site, and this supraphysiological local concentration is the recognized cause of the clinical complication of unwanted heterotopic (ectopic) bone or soft-tissue ossification seen with high-dose recombinant BMP-2 products. Sustained, cell-produced BMP-2 delivers a much lower, more physiological local concentration continuously over the weeks-long timescale of bone remodelling, reducing this ectopic-ossification risk while still providing an effective, uninterrupted osteoinductive signal for as long as it is needed. Second, because the transduced cells themselves persist and remodel with the forming bone, the therapeutic signal automatically tracks the construct's own biological timescale (linking directly back to Question 3's point that a scaffold/signal mismatched to the host-response and remodelling timeline is what drives poor outcomes), rather than requiring the engineer to separately predict and pre-load a fixed release profile as in a passive growth-factor-eluting system like the VEGF microspheres of Question 4(b).
A load-bearing long-bone segmental defect — too large to heal by the body's own repair capacity — is the clinical scenario where a BMP-2-gene-modified, cell-seeded, osteoconductive scaffold construct offers the clearest advantage over either an inert bone-graft substitute alone or a single high-dose recombinant BMP-2 bolus, combining sustained osteoinductive signalling with the structural scaffold support the defect needs to heal without ectopic bone formation at adjacent soft tissue.
